EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes

Maaike C Swets iD, Zsuzsa Bakk, Annette C Westgeest iD, Felicia Ruffin iD, Rachel Korn iD, Jean-Francois Jabbour iD, Priscilla La iD, Luke Tysall iD, Simon Dewar, Rebecca K Sutherland, Mark G J de Boer iD, Geert H Groeneveld und 5 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf655 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Maaike C Swets und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Leiden University Medical Center, Leiden University, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Bacteremia, Staphylococcal Infections, Staphylococcus aureus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edinburgh Clinical Academic Track, Wellcome Trust, Chief Scientist Office.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical heterogeneity in Staphylococcus aureus bacteremia (SAB) complicates clinical management and research. We have previously identified 5 clinically distinct subphenotypes of SAB associated with differences in outcomes and response to adjunctive rifampicin. Here, we aimed to identify these subphenotypes in geographically diverse observational cohorts, including a higher prevalence of methicillin-resistant S. aureus (MRSA) bacteremia and the USA300 clone.

Methods

We studied 3 cohorts of adults with SAB from observational studies: a UK retrospective study (Edinburgh cohort 2; n = 463); a Dutch prospective study (IDISA [Improved Diagnostic Strategies in Staphylococcus aureus bacteremia study]; n = 490); and a prospective US study (SABG-PCS [Staphylococcus aureus Bacteremia Group Prospective Cohort Study]; n = 755). Subphenotypes were identified from routinely available clinical data using latent class analysis.

Results

Patients from the SABG-PCS cohort had greater multimorbidity and more MRSA bacteremia (40.2% [303 of 755]), including infection with the USA300 clone (14.7% [111 of 755]). Five distinct subphenotypes were identified in each cohort: (1) older age and cardiometabolic multimorbidity; (2) nosocomial acquisition and intravenous catheter portal of entry; (3) community acquisition and metastatic infection; (4) chronic kidney disease; and (5) younger age, injection drug use, and metastatic infection. Bacterial genotypes varied substantially between the Edinburgh 2 and SABG-PCS cohorts but did not differ between subphenotypes within each cohort. 90-day mortality was highest in subphenotype A, and persistent bacteremia in subphenotypes C and E.

Conclusions

We have reproducibly identified 5 clinical subphenotypes of SAB in observational cohorts including diverse bacterial genetic lineages and a cohort with a high prevalence of MRSA and USA300 bacteremia. These robustly reproducible clinical subphenotypes provide a framework to rationalize the heterogeneity intrinsic to SAB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteremiaStaphylococcal InfectionsStaphylococcus aureusHumansMaleFemaleMiddle AgedAgedProspective StudiesMethicillin-Resistant Staphylococcus aureusPhenotypeRetrospective StudiesAdultUnited KingdomAged, 80 and overUnited StatesAnti-Bacterial AgentsGenotypeNetherlands

Stichwörter der Autor:innen

Staphylococcus aureusMRSAbacteremiapatient stratificationsubphenotypes

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Leiden University Medical Center, Leiden University, Leiden, The Netherlands.
  • Department of Internal Medicine, Haaglanden Medical Center, The Hague, The Netherlands.
  • Department of Methodology and Statistics, Leiden University, Leiden, The Netherlands.
  • Division of Infectious Diseases and International Health, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
  • Medical Microbiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
  • Clinical Infection Research Group, Western General Hospital, Edinburgh, United Kingdom.

ORCID-Profile: Maaike C Swets, Annette C Westgeest, Felicia Ruffin, Rachel Korn, Jean-Francois Jabbour, Priscilla La, Luke Tysall, Mark G J de Boer, David H Dockrell, Thomas W van der Vaart, Vance G Fowler, Clark D Russell

Förderung

  • Edinburgh Clinical Academic Track
  • Wellcome Trust
  • Chief Scientist Office
  • Royal College of Physicians of Edinburgh
  • NIH HHS
  • MRC
  • AMR
  • National Institutes of Health

Zitieren

APA

Swets, M. C., Bakk, Z., Westgeest, A. C., Ruffin, F., Korn, R., Jabbour, J. F., La, P., Tysall, L., Dewar, S., Sutherland, R. K., de Boer, M. G. J., Groeneveld, G. H., Dockrell, D. H., van der Vaart, T. W., Fowler, V. G., Russell, C. D., & IDISA study team (2026). Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf655

Vancouver

Swets MC, Bakk Z, Westgeest AC, Ruffin F, Korn R, Jabbour JF, et al. Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf655

BibTeX
@article{Swets2026,
  author = {Swets, Maaike C and Bakk, Zsuzsa and Westgeest, Annette C and Ruffin, Felicia and Korn, Rachel and Jabbour, Jean-Francois and La, Priscilla and Tysall, Luke and Dewar, Simon and Sutherland, Rebecca K and de Boer, Mark G J and Groeneveld, Geert H and Dockrell, David H and van der Vaart, Thomas W and Fowler, Vance G and Russell, Clark D and IDISA study team, IDISA study team},
  title = {Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf655}
}
Kostenlos starten →